The contraceptive vaginal ring

Jill Edwardson, Roxanne Jamshidi

Research output: Contribution to journalReview article

Abstract

The contraceptive vaginal ring offers effective contraception that is self-administered, requires less frequent dosing than many other forms of contraception, and provides low doses of hormones. NuvaRing (Organon, Oss, The Netherlands), the only contraceptive vaginal ring approved for use in the United States, contains etonogestrel and ethinyl estradiol. It is inserted into the vagina for 3 weeks, followed by a 1-week ring-free period, and works by inhibiting ovulation. Most women note a beneficial effect on bleeding profiles and are satisfied with NuvaRing. Commonly reported adverse events include vaginitis, leukorrhea, headaches, and device-related events such as discomfort. Serious adverse events are rare. In Chile and Peru, progesterone-only vaginal contraceptive rings are available for nursing women. Studies are ongoing examining new formulations of vaginal contraceptive rings.

Original languageEnglish (US)
Pages (from-to)133-139
Number of pages7
JournalSeminars in reproductive medicine
Volume28
Issue number2
DOIs
StatePublished - Apr 13 2010

Keywords

  • NuvaRing
  • Vaginal contraception
  • Vaginal ring

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Endocrinology
  • Obstetrics and Gynecology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'The contraceptive vaginal ring'. Together they form a unique fingerprint.

  • Cite this